Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
The replay of the webcast will be available on the "For Investors/Events" page of the Relmada website for 90 days following the conference. Conference being held November 19-21, 2024
2024年11月19日至21日舉行會議
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024.
Relmada Therapeutics公司（納斯達克：RLMD、「Relmada」、「該公司」）是一家針對中樞神經系統（CNS）疾病的生物技術公司，今天宣佈公司首席執行官（CEO）Sergio Traversa將於2024年11月20日星期三在Jefferies倫敦醫療保健大會上發表演講。
Jefferies London Healthcare Conference details:
Jefferies倫敦醫療保健大會詳情：
| Presentation: | Wednesday, November 20, 2024 at 12:00 PM GMT |
| Speaker: | Sergio Traversa, CEO |
| Registration: | Webcast link |
| 演示： | 2024年11月20日星期三上午12:00英國格林尼治標準時間 |
| 發言人： | Sergio Traversa，首席執行官 |
| 註冊： | 網絡視頻鏈接 |
The replay of the webcast will be available on the "For Investors/Events" page of the Relmada website for 90 days following the conference.
網絡研討會的重播將在relmada therapeutics網站的"For Investors/Events"頁面上提供，持續90天。
About Relmada Therapeutics, Inc.
關於Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. The Company is also developing REL-P11, a proprietary low-dose psilocybin, as an investigational agent for metabolic disease. Learn more at .
Relmada Therapeutics是一家專注於中樞神經系統疾病治療的晚期生物技術公司，主要關注重性抑鬱症（MDD）。Relmada經驗豐富且專注的團隊致力於改善患者及其家人的生活。Relmada的主導項目REL-1017是一種新的化學實體（NCE）和新型NMDA受體（NMDAR）通道阻滯劑，優先靶向高活性通道同時保持生理性穀氨酸能神經傳導。REL-1017正處於開發的晚期階段，作爲成人MDD的輔助治療。該公司還正在開發REL-P11，一種專有的低劑量哌啶，作爲一種治療代謝疾病的研究試劑。 了解更多信息請訪問 。
Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com
投資者聯繫人：
蒂姆·麥卡錫
LifeSci顧問
Tim@LifeSciAdvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
媒體查詢：
企業通訊
media@relmada.com
譯文內容由第三人軟體翻譯。
